DUBLIN, Aug. 5, 2022 /PRNewswire/ -- The "TIM3 InhibitorsTIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering.
The global TIM-3 inhibitorTIM-3 inhibitor market is expected to surpass US$ 1 Billion by 2028 driven by the first drug approval expected to be launched by 2024. The surge in prevalence of cancer across geographies, high demand for targeted therapeutics for cancer management, development of favorable reimbursement policies, and rise in awareness of TIM-3 immune checkpoint inhibitors for the management of cancer due to positive results in combination therapy are the major factors boosting the growth of the market. In addition, the surge in the geriatric population and the increase in technological advancements in screening and diagnosing cancer will supplement the market growth during the forecast period. However, despite these promising long-term responses, the majority of patients failed to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of these patients who initially respond to treatment eventually experience relapse secondary to acquired resistance.
More recently TIM3 has emerged as a potential immune checkpoint inhibitor in the management of cancer. TIM-3 is regulatory of both innate and adaptive immune responses and is expressed on multiple tumor types including effector T cells, monocytes, natural killer cells, and dendritic cells. Apart from this, TIM-3 has been shown to promote immune tolerance, and overexpression of TIM-3 is associated with more advanced stages and poor prognosis of the disease. Owing to this, pharmaceutical companies have designed novel TIM-3 inhibitors across a wide range of cancers. The promising preclinical data has encouraged pharmaceutical companies to develop a clinical pipeline of monoclonal antibodies targeting TIM-3 as an alternative to target cancers. Currently, several anti-TIM-3 monoclonal antibodies have been developed which have shown encouraging responses in clinical trials. However, studies have supported the fact that combined blockade of PD-1 and TIM-3 pathways synergistically improved the CD8 T cell response and viral control. The advancement in the field of biotechnology and their encouraging response in combination therapy have led to the development of bispecific antibodies. Currently, only a few bispecific antibodies have been developed, however with the advancement in the field of genetic engineering, it is expected that bispecific antibodies will emerge as a shining star in TIM-3 therapy owing to several benefits associated with them. Based on this encouraging data, the company is translating the drug into late-stage clinical trials for the management of solid tumors. Apart from this, several other drugs are under development including MBG453, Sym-023, BMS-986258, AZD7789, INCAGN02390, and others which are also present in the initial stages of clinical development. US is currently dominating the global market development for TIM3 Drugs driven by a large number of ongoing clinical trials and the presence of pharmaceutical companies which actively invest in this segment. The US FDA also grants several special designations to expedite the drug development and approval process. For instance, in 2021, US FDA granted fast-track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) in combination with hypomethylating agents. Insight on Emerging TIM3 InhibitorsTIM3 Inhibitors in Development As Monotherapy & combination Therapy Future Market Opportunity Insight From First Drug Approval: 2024 - 2028
Comprehensive Clinical Insight On Biomarker Identified During Clinical Trials
1. TIM3 - Emerging Immune Checkpoint 1.2 Structure & Biology of TIM3 2. TIM3 as Cancer Combination Immunotherapy Target 5.1 TIM3 as Diagnostic Biomarker 5.2 TIM3 as Prognostic Biomarker 6. TIM3 Therapy Targeted Therapeutic Approach 6.1 Small Molecule Immunotherapy
6.2 Monoclonal Antibodies
6.3 Bispecific Antibodies
7.3 By Patient Segment/Disease Stage
10. TIM3 Therapy Future Perspective
10.2 Future Market Opportunity
11.5 Brightpath Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/3yw6uq
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg